Related Experiment Video
Updated: Jul 13, 2026
12:18
The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy
Published on: December 26, 2014
Juvenile myasthenia gravis with prepubertal onset
A Evoli1, A P Batocchi, E Bartoccioni
1Institute of Neurology, Catholic University, Rome, Italy. a.evoli@vsb.it
Neuromuscular Disorders : NMD
|March 27, 1999
Summary
Juvenile myasthenia gravis (JMG) with prepubertal onset is rare. Children with JMG may have severe symptoms and lower antibody rates, but often achieve good outcomes with treatment, unlike older patients who may have thymoma.
Area of Science:
- Neurology
- Pediatrics
- Immunology
Background:
- Juvenile myasthenia gravis (JMG) with prepubertal onset is uncommon.
- Understanding JMG in young children is crucial for effective management.
Purpose of the Study:
- To compare clinical characteristics and treatment responses of prepubertal JMG with later-onset JMG.
- To identify unique features and outcomes in young JMG patients.
Main Methods:
- Retrospective study of 19 prepubertal JMG patients (onset 1.5-9.2 years).
- Comparison with 114 JMG patients with onset up to 20 years.
- Analysis of clinical features, antibody status, and treatment outcomes.
Main Results:
- Prepubertal JMG showed no sex prevalence or other autoimmune diseases.
- Ocular myasthenia was more frequent, but generalized symptoms were severe with respiratory involvement in 8/19.
- Lower anti-acetylcholine receptor antibody rates and higher seronegativity in generalized prepubertal JMG.
- Spontaneous remission occurred in 3/6 patients with onset before age five.
- Thymectomy in prepubertal patients had unclear outcomes due to concurrent immunosuppressive therapy; no thymoma found.
- Most patients achieved good condition with immunosuppressive therapy, similar to older JMG patients.
Conclusions:
- Prepubertal JMG presents distinct features, including severe generalized symptoms and lower antibody detection rates.
- While thymoma is absent, spontaneous remission is possible in very young children.
- Treatment outcomes with immunosuppressive therapy are comparable to older JMG patients, highlighting the importance of medical management.
Related Concept Videos
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...